Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2056 to 2070 of 8775 results

  1. Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over [ID6666]

    Awaiting development Reference number: GID-TA11825 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Orforglipron for managing overweight and obesity [ID6516]

    In development Reference number: GID-TA11650 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  3. Ponatinib for treating recurrent or refractory chronic myeloid leukaemia in people 1 to 17 years when another tyrosine kinase inhibitor is unsuitable [TSID12041]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Deucravacitinib for treating active Sjogren's syndrome [ID6715]

    Awaiting development Reference number: GID-TA11939 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Selinexor with ruxolitinib for treating splenomegaly or symptoms in myelofibrosis untreated with a JAK inhibitor [ID6717]

    Awaiting development Reference number: GID-TA11941 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Selinexor with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 to 4 treatment lines in people who have not had pomalidomide [ID6705]

    Awaiting development Reference number: GID-TA11938 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]

    Awaiting development Reference number: GID-TA11917 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Belzutifan for treating advanced pheochromocytoma or paraganglioma [ID6719]

    Awaiting development Reference number: GID-TA11928 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]

    Awaiting development Reference number: GID-TA11876 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]

    Awaiting development Reference number: GID-TA11923 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Ravulizumab for treating primary IgA nephropathy [ID6703]

    Awaiting development Reference number: GID-TA11919 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Peginterferon alfa-2a for treating polycythaemia vera or essential thrombocythaemia [TSID12325]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. DB-OTO for Hearing loss [ID6728]

    Awaiting development Reference number: GID-TA11911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]

    Awaiting development Reference number: GID-TA11910 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Suspected sepsis in under 16s: recognition, diagnosis and early management

    In development Reference number: GID-NG10466 Expected publication date:  17 February 2027

    NICE guideline
    In development